Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced its participation in two upcoming investor conferences in New York. The H.C. Wainwright 24th Annual Global Investment Conference is scheduled for September 12, 2022, featuring an on-demand corporate presentation at 7:00 a.m. ET. Subsequently, Alector will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference later that day at 5:25 p.m. ET. Webcasts of these events will be accessible on Alector's website for 90 days.
Alector, Inc. (Nasdaq: ALEC) recently reported its Q2 2022 financial results, highlighting revenue growth and significant advancements in its clinical pipeline. The company achieved $79.9 million in collaboration revenue, a significant increase from $6.6 million in Q2 2021, primarily due to the AbbVie Agreement. Alector's cash position stands at $808.9 million, providing operational runway into H2-2024.
The company submitted an IND application for AL044, targeting Alzheimer’s disease, and continues to expand clinical sites for the pivotal INFRONT-3 study of latozinemab (AL001).
Alector, a clinical-stage biotechnology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 2:00 p.m. PT. The live webcast will be accessible on Alector's Investors page, with a replay available for 90 days post-event. Alector is known for its innovative approach in immuno-neurology, targeting immune dysfunction to treat neurodegenerative diseases like Alzheimer’s and frontotemporal dementia.
Alector, Inc. (Nasdaq: ALEC) announced on May 27, 2022, that its board approved an inducement equity grant for Gary Romano, M.D., Ph.D., its new Chief Medical Officer. The grant includes inducement stock options for 369,000 shares and restricted stock units (RSUs) for 92,250 shares, aligned with the 2022 Inducement Equity Incentive Plan. The options have an exercise price of $9.20 per share and vest over four years, while the RSUs vest quarterly over three years, starting September 1, 2022. This move aims to attract talent amid growing operations in immuno-neurology.
Alector, Inc. (Nasdaq: ALEC) reported promising results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab), showing a 54% annual delay in disease progression for FTD-C9orf72 patients compared to controls. The drug increased progranulin levels significantly, supporting its role in treating neurodegenerative diseases. Alector's cash reserves stand at $868.6 million, ensuring operational funds through mid-2024. Leadership has been strengthened with new appointments, enhancing their clinical and financial strategies.
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced its participation in the BofA Securities 2022 Healthcare Conference. The event will occur on May 12, 2022, at 11:20 a.m. PT, and will feature a fireside chat with management. A live webcast can be accessed through the Alector website, with a replay available for 90 days post-event. Alector specializes in therapeutic approaches for neurodegenerative diseases, targeting immune dysfunction in conditions such as Alzheimer's and frontotemporal dementia.
Alector, a biotechnology company focused on immuno-neurology, has appointed Dr. Gary Romano as the new Chief Medical Officer, effective May 23, 2022. Dr. Romano, an expert in neurodegeneration with over 25 years of experience, will oversee clinical development and operations. His previous roles include leadership at Passage Bio and Janssen. The company expressed gratitude to interim CMO Dr. Sam Jackson for his contributions. Dr. Romano aims to advance Alector's pipeline targeting neurodegenerative diseases, enhancing its strategy in clinical research and drug development.
Alector presented promising results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab) in patients with frontotemporal dementia (FTD) carrying the C9orf72 mutation. The trial showed that treatment led to increased levels of progranulin and a trend towards a delay in disease progression by approximately 54% compared to matched controls. After 12 months of treatment, latozinemab was well tolerated, with stability in neurofilament light chain levels and a reduction in GFAP levels, suggesting potential benefits in neurodegenerative disease management.
Alector, a clinical-stage biotechnology company specializing in immuno-neurology, announced presentations at two upcoming investor conferences. The first is at the Barclays Global Healthcare Conference in Miami, scheduled for March 16, 2022, at 3:20 p.m. ET. The second is the Stifel CNS Days Virtual event on March 28, 2022, at 11:30 a.m. ET. Both presentations will be available via live webcasts, with replays accessible for 90 days on Alector's website. Alector aims to treat neurodegenerative diseases by addressing immune dysfunction.
Alector (Nasdaq: ALEC) announced an oral presentation at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases, scheduled for March 15-20, 2022, in Barcelona, Spain. The presentation will showcase the 12-month results from the INFRONT-2 Phase 2 study of AL001 in Frontotemporal Dementia patients with a C9orf72 mutation. Alector will also host a conference call on March 15, 2022, at 8:30 a.m. ET to discuss these findings.
For more details, visit www.alector.com.